June 2025

DRAGENTM v4.4 - Powering a comprehensive genome with accuracy, speed, and ease of use

DRAGEN v4.4 brings multiomics pipelines for new assays including Illumina Single Cell 3’RNA Prep, Illumina Protein Prep and Illumina 5-base solution as well as powerful oncology applications in an easy-to-use package for clinical research. Notably, improvements include a 30% leap in structural variant calling accuracy.

Did you know?

Give me details

Illumina spatial transcriptomics technology* achieves 4x greater resolution than other solutions currently available.

Illumina spatial transcriptomics technology* will support the construction of cell atlas maps for characterization of biological pathways and disease mechanisms. The scale of this unbiased whole-transcriptome profiling with cellular resolution enables research studies that were previously considered unfeasible.

*Planned for commercial release in 2026

Read NowOpens in a new window.

What is the function of PromoterAI, the groundbreaking new deep learning algorithm?

PromoterAI is the new deep learning algorithm, developed by Illumina Artificial Intelligence Laboratory, that identifies potential disease-causing variants within “promoter” sequences in the human genome.
This algorithm will empower clinical researchers to better understand the causes of rare genetic diseases and cancer and drive the discovery of novel therapeutic targets in biobank-scale cohorts.

Read NowOpens in a new window.

Innovations to enable multiomics

1

TGen study uses Illumina Spatial Technology to characterize dysregulation in pulmonary fibrosis

Learn More

TGen study uses Illumina Spatial Technology to characterize dysregulation in pulmonary fibrosis

Early access user, Dr. Nicholas Banovich of Translational Genomics Research Institute (TGen) describes how the high sensitivity and large capture area of Illumina spatial technology has provided new insights for his research in pulmonary fibrosis contributing to a model of epithelial remodeling in the disease.

Back Watch NowOpens in a new window.

2

Decode DNA and methylation together with the Illumina 5-base solution 

Learn More

Decode DNA and methylation together with the Illumina 5-base solution 

Fiona Kaper, VP and Head of Assay R&D at Illumina, discusses the innovative 5-base solution that simplifies and scales multiomic analysis. Discover how Illumina 5-base chemistry enables dual genomic and epigenomic insights in one assay, providing genetic variant and DNA methylation data with exceptional accuracy, simplicity, and scale. 

Back Watch NowOpens in a new window.

Multiomics in action

Publication highlights from the research community

Transcriptomics

Single-cell

Genomics

YY1 mutations disrupt corticogenesis through a cell type specific rewiring of cell-autonomous and non-cell-autonomous transcriptional programs

The group of Giuseppe Testa, at Human Technopole in Milan, in collaboration with other research teams around the world, have published results from a study using advanced stem cell models to characterize cellular and molecular changes underlying Gabriele-de Vries Syndrome (GADEVS), a rare neurodevelopmental disorder. Their study demonstrated how YY1 mutations cause developmental defects at cellular, structural, and molecular levels, opening a path to identify potential therapeutic targets that may be applicable in other neurodevelopmental disorders.

Learn more about Illumina Stranded mRNA Prep

Publication LinkOpens in a new window.

Transcriptomics

Single-cell

Genomics

Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics

Using single-cell genomics, scientists collaborating across multiple countries published new insights on potential treatments for glioblastoma (GBM), an incurable brain tumor that exhibits high recurrence after treatment. In this comprehensive analysis of GBM at single-cell resolution, recurrence trajectories showed high diversity. Their results indicate that specific transcriptional trajectories could be assigned to subsets of tumors for more defined stratification of recurrence and potentially opens the path to future specific treatment strategies.

Learn about Illumina single-cell RNA-sequencing solution

Publication LinkOpens in a new window.

Transcriptomics

Single-cell

Genomics

Tumor-Infiltrating Clonal Hematopoiesis

Using samples from TRACERx and MSK-IMPACT cohorts, scientists from cancer research institutes in France, Netherlands, UK, and New York, published this study which characterizes tumor-infiltrating clonal hematopoiesis (TI-CH) where clonal hematopoiesis of indeterminate potential (CHIP) mutations with high variant-allele frequencies can be detected in tumors. Findings from the study show that TI-CH remodeled the tumor immune microenvironment and accelerated tumor organoid growth, indicating increased risk of recurrence or death for non–small-cell lung cancer (NSCLC) patients.

Learn about Illumina solutions for comprehensive genomic profiling

Publication LinkOpens in a new window.

Educational resources ​to learn more

On Demand Recordings
Epigenetics: the full picture
On Demand Recordings
Epigenetics: the full picture

Register now to access the on-demand recordings from Epigenetics: the full picture 2025. Highlights from our 6th edition include presentations on epigenetics in diabetes, obesity, cancer research and animal health.


eBook
Understanding DNA methylation and its applications for human disease research
eBook
Understanding DNA methylation and its applications for human disease research
This eBook covers DNA methylation and its applications in the study of human diseases and other phenotypes. It covers epigenome-wide association studies (EWAS), including considerations for study design, sample types, and data analysis.
On Demand Recordings
DRAGEN v4.4 - comprehensive secondary analysis
On Demand Recordings
DRAGEN v4.4 - comprehensive secondary analysis
DRAGEN v4.4 will power samples to insights multiomic workflows with secondary analysis pipelines that are optimized for the latest Illumina assays. Hear about all the new features in this technical webinar on demand.

Reach out to Illumina today

Let’s discuss your next multiomics project. 
Provide some brief details on what you would like to discuss with our experts.  An Illumina representative will reach out to you.
Contact UsOpens in a new window.